# Chemokine receptor antagonists

Chemokines are chemotactic cytokines, leads to leukocyte recruitment and activation. In malignancies altered expression can induce angiogenesis, tumor cell proliferation, and metastasis. Chemokine receptor antagonists inhibit chemokine receptors expressed on cancer and stromal cells.

## Filter by content:

### Types
- Newly diagnosed multiple myeloma
- Plasma cell dyscrasias
- Relapsed/refractory multiple myeloma

### Therapeutics
- Auto-HSCT
- Bortezomib
- Carfilzomib
- Cyclophosphamide
- Daratumumab
- Dexamethasone
- Immune modulators
- Lenalidomide
- Motixafortide
- Plerixafor
- Proteasome inhibitors
- Thalidomide

### Congresses
- ASH 2019
- COMy 2020
- EBMT 2020

### Trials
- ALCYONE
- CASSIOPEIA
- GENESIS
- GRIFFIN
- IFM2009
- PERSEUS
- SWOG S0777

### Expert Opinions

### Educational Resources
- Drug approvals

## All Therapeutics

### Chemokine receptor antagonists
- [Motixafortide](/content/therapeutics/chemokine-receptor-antagonists/motixafortide/index.html)
- [Plerixafor](/content/therapeutics/chemokine-receptor-antagonists/plerixafor/index.html)

### Additional Therapeutics
- [Bortezomib](/content/therapeutics/proteasome-inhibitors/bortezomib/index.html)
- [Carfilzomib](/content/therapeutics/proteasome-inhibitors/carfilzomib/index.html)